Senzar Asset Management LLC Has Lowered Position in Halozyme Therapeutics INC (HALO) as Stock Rose

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment increased to 1.47 in Q2 2019. Its up 0.03, from 1.44 in 2019Q1. It is positive, as 16 investors sold HALO shares while 44 reduced holdings. 28 funds opened positions while 60 raised stakes. 105.70 million shares or 8.25% less from 115.20 million shares in 2019Q1 were reported. Invesco holds 0.02% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 5.39 million shares. Adage Cap Prns Group Ltd Liability Com accumulated 0.02% or 450,000 shares. Dimensional Fund Advsr LP owns 209,392 shares for 0% of their portfolio. Granite Investment Prtnrs invested 0.79% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Verition Fund Mgmt Limited Liability Corporation reported 38,570 shares stake. Fmr Lc reported 2.74 million shares or 0.01% of all its holdings. Utd Automobile Association holds 0% or 45,778 shares. Numerixs has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Moreover, Gotham Asset Mgmt Limited Liability Corp has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Los Angeles Management And Equity Inc holds 0.02% or 210,314 shares in its portfolio. Parametric Port Associate Limited Liability holds 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 141,131 shares. 338,060 were reported by Alliancebernstein L P. Kennedy Capital Management reported 177,520 shares. 43,643 are held by M&T State Bank Corporation. The Massachusetts-based Geode Mgmt Ltd Liability Company has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Senzar Asset Management Llc decreased its stake in Halozyme Therapeutics Inc (HALO) by 6.29% based on its latest 2019Q2 regulatory filing with the SEC. Senzar Asset Management Llc sold 257,074 shares as the company’s stock rose 5.07% . The hedge fund held 3.83M shares of the health care company at the end of 2019Q2, valued at $66.53M, down from 4.09M at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Halozyme Therapeutics Inc for a number of months, seems to be less bullish one the $2.35 billion market cap company. The stock increased 2.62% or $0.41 during the last trading session, reaching $16.05. About 1.38M shares traded or 83.21% up from the average. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has declined 1.34% since October 12, 2018 and is downtrending. It has underperformed by 1.34% the S&P500.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on November, 5. They expect $-0.13 EPS, up 31.58 % or $0.06 from last year’s $-0.19 per share. After $-0.10 actual EPS reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 30.00 % negative EPS growth.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: which released: “Is Halozyme Therapeutics, Inc. (HALO) A Good Stock To Buy? – Yahoo Finance” on June 11, 2019, also with their article: “Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call – PRNewswire” published on July 23, 2019, published: “Halozyme reports positive results from Perjeta + Herceptin combination study – Seeking Alpha” on September 13, 2019. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: and their article: “Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX┬« Utilizing ENHANZE┬« Technology – PRNewswire” published on July 19, 2019 as well as‘s news article titled: “Halozyme on track for key data readout in Q4 – Seeking Alpha” with publication date: June 12, 2019.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.